Novolin Injection, Suspension
NDC Package 50090-0403-0

11-digit billing NDC: 50090040300 · Billing unit: ML · 10 ML per package

Package Information

Novolin (human insulin) injection is nOVOLIN 70/30 is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.Limitations of Use:In NOVOLIN 70/30, the proportions of short-acting and intermediate-acting insulins are fixed and do not allow for basal versus prandial dose adjustments. This formulation utilizes a injection, suspension delivery system. Marketed by A-s Medication Solutions, this product is identified by NDC 50090-0403 and is authorized under FDA application BLA019991.

Identification & Billing

NDC Package Code
50090-0403-0
Package Description
1 VIAL in 1 CARTON / 10 mL in 1 VIAL
Product Code
11-Digit Billing Format
50090040300
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
Units Per Package
10 ML
RxNorm Crosswalk
  • RxCUI: 213442 - NovoLIN 70/30 Injectable Suspension
  • RxCUI: 213442 - insulin isophane, human 70 UNT/ML / insulin, regular, human 30 UNT/ML Injectable Suspension [Novolin]
  • RxCUI: 213442 - Novolin 70/30 Injectable Suspension
  • RxCUI: 213442 - Relion Novolin 70/30 Injectable Suspension
  • RxCUI: 311048 - insulin, human isophane / insulin regular 70/30 Injectable Suspension

Clinical Specifications

Proprietary Name
Novolin 70/30
Non-Proprietary Name
Human Insulin
Substance Name
Insulin Human
Dosage Form
Injection, Suspension - A liquid preparation, suitable for injection, which consists of solid particles dispersed throughout a liquid phase in which the particles are not soluble. It can also consist of an oil phase dispersed throughout an aqueous phase, or vice-versa.
Administration Route
Subcutaneous - Administration beneath the skin; hypodermic. Synonymous with the term SUBDERMAL.
Active Ingredient(s)
Usage Information
NOVOLIN 70/30 is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.Limitations of Use:In NOVOLIN 70/30, the proportions of short-acting and intermediate-acting insulins are fixed and do not allow for basal versus prandial dose adjustments.

Regulatory & Marketing

Labeler Name
A-s Medication Solutions
Product Type
Human Otc Drug
FDA Application #
BLA019991
Marketing Category
BLA - A product marketed under an approved Biologic License Application.
Start Marketing Date
06-25-1991
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 50090-0403-0 identifies a specific commercial package of 1 vial in 1 carton / 10 ml in 1 vial of Novolin 70/30, a human over the counter drug labeled by A-s Medication Solutions. This product is billed per "ML" milliliter and contains an estimated amount of 10 billable units per package. This injection, suspension is formulated for subcutaneous use and contains insulin human as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by A-s Medication Solutions on June 25, 1991. The current certification is valid through December 31, 2026.

How is this A-s Medication Solutions product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 50090040300. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. There are 10 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
50090-0403-0
11-Digit CMS (5-4-2)
50090-0403-00

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.